Today: 10 June 2026
Browse Category

NASDAQ:PGEN 15 August 2025 - 14 May 2026

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
14 May 2026
·
Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen shares surged nearly 30% intraday on November 14, trading around $4.90–$5.00 after reporting Q3 revenue of $2.92 million, far above expectations. The company’s PAPZIMEOS therapy for recurrent respiratory papillomatosis is fully launched in the U.S., with over 100 patients enrolled and broad insurance coverage. Precigen has also filed for European approval of PAPZIMEOS.
14 November 2025
···
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

The FDA approved Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis, after trials showed 51.4% of adults avoided surgery for 12 months. Cardinal Health will acquire Solaris Health for $1.9 billion in cash, expanding its specialty care network. RemeGen’s telitacicept met its Phase 3 endpoint in primary Sjögren’s syndrome in China. Response Therapeutics’ RDX-002 pill curbed weight regain in a Phase 2 trial.
15 August 2025
···

Stock Market Today

  • AutoNation (AN) Shares Rise Amid Mixed Fair Value Signals, Analysts See 20% Undervaluation
    June 10, 2026, 10:19 AM EDT. AutoNation (AN) shares gained 4.9% in one day and 2.0% over the past week, though they are down 5.6% year-to-date, contrasting with a 5-year total shareholder return of 107.4%. Despite recent share price momentum cooling, analysts see potential value, assigning a consensus price target of $242.75, about 20% above the recent $195.0 closing price. Price targets vary between $208.0 and $300.0, reflecting uncertainty over earnings sustainability and market multiples. The company shows steady revenue and net income growth, but future margin pressures remain due to competition from direct-to-consumer models and faster electric vehicle adoption. The fair value estimate hinges on the traditional dealership model retaining its competitive edge. This mixed outlook highlights investor caution amid evolving automotive market dynamics.

Latest articles

Go toTop